Nature Communications (Nov 2017)
Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors
Abstract
“Although aberrant promoter DNA hypermethylation is a hallmark of cancer, it is not clear whether it is sufficient to drive transformation. Here, the authors use CRISPR-dCas9 to perform hit-and-run epigenetic editing, which prevents senescence entry in primary breast cells from healthy donors.”